Archives
-
AG-120 and CD44 Metabolism in IDH-Mutant Leukemia
2026-10-07
AG-120, also known as ivosidenib, is a mutant IDH1 inhibitor used in research on 2-hydroxyglutarate biology and AML differentiation. Recent work identifies CD44-mediated metabolic rewiring as a dependency in IDH-mutant leukemia, helping sustain NADPH and R-2HG production. This overview compares the mechanistic evidence, clarifies what it does and does not establish about combined targeting, and outlines major limitations in translating cell and model findings to patients.
-
From FLAG Tags to Mechanistic Translation
2026-10-07
A thought-leadership perspective on how the FLAG tag Peptide (DYKDDDDK) can support more interpretable recombinant protein studies, using new evidence on BicD, MAP7, and kinesin-1 to frame tag selection as a question of assay validity rather than convenience.
-
YC-1: Evidence in Hypoxia and Pain Research
2026-10-06
YC-1 is a research small molecule associated with soluble guanylyl cyclase activation and HIF-1α signaling. This overview compares supplier-reported hypoxia and cancer applications with findings from a 2026 rat study of trigeminal neuralgia, emphasizing what is established, what remains hypothetical, and where evidence cannot yet be extrapolated.
-
AG-120 and CD44 Metabolic Rewiring in IDH1 AML
2026-10-06
A source-grounded overview of AG-120 (ivosidenib) research, mutant IDH1 biology, CD44-mediated metabolic rewiring, differentiation findings, resistance questions, and the limits of current evidence.
-
Wnt-C59: From Ligand Supply to Exosomal Wnt
2026-10-05
Wnt-C59 is a selective PORCN inhibitor for examining how Wnt ligand availability shapes canonical signaling. This article connects its cancer-biology evidence with a 2024 study of lithium-driven exosomal Wnt10a secretion, emphasizing causal interpretation, translational boundaries, and testable research questions.
-
Dimethyloxalylglycine (DMOG): Product Overview
2026-10-05
Dimethyloxalylglycine (DMOG; SKU A4506) is listed by APExBIO as a research-use-only chemical tool for conceptual studies of HIF-associated oxygen sensing and hypoxia signaling. No matched paper evidence was provided, so independent performance and outcome claims are not assessed here.
-
p-Tau Ser356, NUAK Inhibition, and Alzheimer’s
2026-10-04
Taylor et al. investigated tau phosphorylated at serine 356 as a pathology-associated molecular feature and examined whether NUAK inhibition alters this species in mouse and human brain tissue. The study’s most important contribution is its comparison of mouse organotypic slices with live human brain slices, revealing that WZ4003 produced broader tau and neuronal-protein changes in mouse tissue but a more selective reduction of p-tau Ser356 in human slices.
-
SB 431542 and Human Brain Organoid Signaling
2026-10-03
SB 431542 is an ALK5 inhibitor that can serve as a pathway-dissection tool in human cerebral organoid research. This article connects its receptor selectivity and Smad2 effects with the 2024 olanzapine–NODAL/FOXH1 study while clarifying evidence limits and causal interpretation.
-
FOXO3–YAP Metabolic Control in Hepatocellular Carcinoma
2026-10-02
The reference study identifies FOXO3 as a tumor-suppressive regulator that simultaneously restrains glycolysis and glutaminolysis in hepatocellular carcinoma through direct repression of YAP transcription. Its combination of promoter-level mechanism, pharmacological activation, in vivo validation, and patient-derived organoid testing supports the FOXO3/YAP axis as a preclinical strategy for targeting metabolic plasticity.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-10-01
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and formulate poorly water-soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This guide covers dossier-based handling, inclusion-complex workflows, and quality checks; it does not establish clinical efficacy, universal bioavailability improvement, or suitability for unrelated applications.
-
Ciprofloxacin Hydrochloride: Assay Workflows
2026-10-01
Ciprofloxacin hydrochloride supports more than routine antibacterial testing: it enables dose–response, antibiotic-combination, and single-cell DNA-damage workflows. This guide translates growth-dependent ciprofloxacin–tetracycline antagonism into practical setup, controls, troubleshooting, and assay-selection decisions.
-
Sulforaphane Workflows for Stress and Inflammation
2026-09-30
Sulforaphane connects Keap1–Nrf2 activation with redox-sensitive inflammation and cancer research. This practical guide translates those mechanisms into cell-based assays, NLRP3-focused workflows, and troubleshooting strategies for reproducible experimental design.
-
Auranofin in Redox-Metabolic Cancer Research
2026-09-30
Auranofin is a thioredoxin reductase inhibitor for investigating how redox disruption intersects with cancer metabolism. This article translates FOXO3/YAP findings in hepatocellular carcinoma into practical assay strategies while defining what Auranofin can—and cannot—demonstrate.
-
Laminin (925-933): Practical Assay Guide
2026-09-29
Laminin (925-933) is a defined Laminin B1 chain peptide for testing cell attachment, receptor-related competition, and chemotaxis workflows without using full-length laminin. This dossier-based guide covers preparation and QC for in vitro research; the product is not validated here for diagnosis, therapy, or direct clinical translation.
-
Wnt-C59 and the Logic of Wnt Secretion Assays
2026-09-29
Wnt-C59 is a highly potent PORCN inhibitor for dissecting ligand secretion, Wnt/β-catenin signaling, and cancer biology. This article develops a mechanism-first assay framework that connects Wnt-C59 studies with new findings on exosomal Wnt10a secretion and osteogenesis.